Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.
PLEASANTON, Calif.–(BUSINESS WIRE)–RadiusXR, the trailblazer in Digital Health, announces the publication of its groundbreaking NOVA Clinical Trial in Translational Vision Science and Technology (TVST), a prestigious journal by the Association for Research in Vision and Ophthalmology (ARVO). This milestone publication confirms RadiusXR’s unwavering commitment to advancing ocular health and heralds a new era in visual field testing.
“Our proprietary technology, combined with spatial computing, delivers unparalleled accuracy and precision, revolutionizing the diagnosis and management of ocular conditions.”
The NOVA Clinical Trial has revealed remarkable findings, including statistical non-inferiority to current clinical standards for sensitivities at individual test locations, glaucoma staging using Medicare definitions, and an exceptionally high correlation of 0.94 in mean deviation.1 These results underscore the unparalleled accuracy and reliability of RadiusXR’s approach to visual field testing for head-mounted virtual reality perimetry.
Moreover, unlike other virtual reality perimeters (VRPs), RadiusXR measures vision within the photopic range, aligning with existing visual field platforms’ standards. This alignment enables consistent clinical training and facilitates comparison to patients’ prior examinations, as normative databases and mean deviation/pattern standard deviation (MD/PSD) plots are based on the photopic range. RadiusXR’s steadfast adherence to industry standards ensures seamless integration into clinical practice and enhances patient care.
“The publication of the NOVA Clinical Trial in TVST reaffirms RadiusXR’s position as the leader in visual field testing innovation,” remarked Ammad Khan, RadiusXR’s Chief Executive Officer. “Our proprietary technology, combined with spatial computing, delivers unparalleled accuracy and precision, revolutionizing the diagnosis and management of ocular conditions.”
Dr. Thomas Samuelson, a distinguished ophthalmologist at Minnesota Eye Consultants in Minneapolis, expressed, “The findings from the NOVA Clinical Trial are truly groundbreaking. RadiusXR’s innovative approach to visual field testing represents a significant advancement in the field of ophthalmology. This technology can potentially revolutionize how we diagnose and manage ocular conditions, ultimately improving patient outcomes and quality of life.”
In July 2023, RadiusXR announced it entered into a collaboration and marketing agreement with Glaukos Corporation, a leading ophthalmic pharmaceutical and medical technology company, whereby Glaukos became the exclusive sales agent to market, promote, and solicit orders for RadiusXR in the United States. Radius continues to lead development and commercialization efforts for RadiusXR.
Jack Boreham is the editorial director and account executive at the Digital Twin Insider: the leading digital twin publication globally. Jack has been at the forefront of the platform's growth as a digital twin specialist - writing and advising projects in the Digital Twin space for over two years.
[email protected]
We use cookies to improve your experience on our site. By continuing to browse our site, you consent to our use of cookies. For more details, you can manage your preferences under "Settings".
Read our cookie policy
One of our team will be in touch to learn more about your requirements so we can find the perfect solution for your business. Please email us at [email protected] if your request is urgent.
Stay ahead in the virtual realm with Digital Twin Insider, subscribe to our newsletter today
